deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02677805

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (BLESS-II)

Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study

Sponsor: Croma-Pharma GmbH

Conditions Glabellar Frown Lines
Interventions Botulinum Toxin A Botulinum Toxin A - Open Label Placebo
Updated 14 times since 2017 Last updated: Mar 11, 2025 Started: Mar 30, 2016 Primary completion: Sep 15, 2016 Completion: Nov 3, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02677805, this PHASE3 trial focuses on Glabellar Frown Lines and remains completed. Sponsored by Croma-Pharma GmbH, it has been updated 14 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Mar 2020 · 12 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 17 months · monthly snapshot

Change History

14 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2022 — Jun 2022 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

  2. Mar 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Mar 2019 — Mar 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Sep 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Unknown Status → Active Not Recruiting

  5. Jul 2018 — Sep 2018 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Croma-Pharma GmbH
Data source: Croma-Pharma GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations